Gynecology Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Gynecology Drugs Market Analysis
The gynecology drugs market is expected to register a CAGR of 6.2% over the forecast period.
- The COVID-19 pandemic considerably impacted the management of patients with gynecologic diseases during the initial pandemic. For instance, according to a study published by SAGE Journals in August 2022, the management of gynecological cancers suffered during the pandemic, partly due to lockdowns and partly due to directing resources to manage COVID-19 patients. It was also stated that modification of gynecological cancer management during the pandemic was recommended. Therefore, such instances indicated that the market witnessed slow growth during the pandemic. However, with the easing of restrictions and lockdowns and declining cases of COVID-19, the market was expected to witness considerable growth over the forecast period.
- The major factors driving the growth of the studied market include the increasing burden of gynecological diseases and the rise in healthcare awareness along with the increasing aging female population.
- The rising incidence of various gynecological diseases is projected to continue in the future, which is likely to fuel the demand for efficient treatment, driving the global gynecological drugs market over the forecast period. According to an article published by Cureus in August 2022, a study was conducted in India, which showed that the prevalence of polycystic ovary syndrome (PCOS) was 6.8% among the study participants. The source also stated that polycystic ovary syndrome is a very common health problem among adolescents and young girls. Thus, the high burden of such diseases is expected to boost the market growth.
- Moreover, according to the data published by the National Cancer Institute in January 2022, the estimated number of new cervical cancer cases in 2022 was around 14,100 in the United States, which is around 0.7% up from previous years of all new cancer cases. Similarly, as per the report published by the American Cancer Society in January 2022, around 19,880 women were expected to receive a new diagnosis of ovarian cancer in 2022. Therefore, such a high prevalence of gynecology cancers is expected to fuel the demand for gynecology drugs, thereby propelling the market growth.
- Moreover, the rising developments by key market players are also enhancing the market growth. For instance, in May 2021, Myovant Sciences and Pfizer Inc. received approval from the United States Food and Drug Administration (USFDA) for MYFEMBREE, the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.
- However, the high cost and stringent regulatory framework that delays the approval of products are likely to impede market growth over the forecast period.
Gynecology Drugs Market Trends
Non-hormonal Therapy Segment is Expected to Witness High Growth Over the Forecast Period
- The non-hormonal therapy segment is expected to have a high growth rate over the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of these products due to proven efficiency in the treatment, rapid advancements in new product development with reduced side effects, and the availability of a wide range of marketed products. Furthermore, the disadvantages of hormonal therapy, such as the risk of breast cancer and other complications associated with these products, are expected to foster the demand for non-hormonal products during the forecast period.
- Various studies are being conducted to measure the effectiveness and advantages of non-hormonal therapy. For instance, according to the study published by PubMed in March 2022, NLRP3/IL-1β is involved in the pathogenesis of endometriosis, and the NLRP3 inhibitor may be useful for suppressing ovarian endometriosis and improving the function of ovaries with endometriosis.
- In addition, increasing clinical trials for launching new non-hormonal therapy drugs for various symptoms are also surging the segment growth. For instance, in October 2021, Bayer commenced the Phase III clinical development program OASIS, which aims to evaluate the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms during menopause.
- Therefore, increasing studies on non-hormonal therapy and clinical trials are expected to increase awareness of the application of non-hormonal therapy in treating gynecological cancers. Hence, significant segment growth is anticipated over the forecast period.
North America is Expected to Hold a Significant Share in the Gynecology Drugs Market
- North America is expected to hold a significant share of the gynecology drugs market over the forecast period. This dominance is mainly owing to rising incidences of breast cancer, menopausal disorders, polycystic ovary syndrome, and others due to busy lifestyles and the rise in stress among the women in the region.
- For instance, as per the report published by the Canadian Cancer Society in May 2022, it is estimated that around 1,450 Canadian women will be diagnosed with cervical cancer in 2022. Moreover, the availability of advanced healthcare infrastructure, an increase in government expenditure for women's healthcare awareness, and the senior women population, along with early product launches with enhanced quality in the region, are expected to contribute to the market growth over the forecast period.
- Key product launches, high concentration of market players or manufacturers' presence, acquisition and & partnerships among major players, and the high prevalence of gynecological cancers in the United States are some of the factors driving the growth of the gynecology drugs market in the region.
- For instance, as per the report published by the American Cancer Society in January 2022, breast cancer is the most common cancer in women in the United States, which is about 30.0% or 1 out of 3 of all new female cancers each year. Such high prevalence is anticipated to surge the demand for gynecology drugs, thereby propelling the market growth in the United States over the forecast period.
Gynecology Drugs Industry Overview
The gynecology drugs market is moderately competitive and consists of several major players. Some prominent players in the market are implementing various strategies, such as launching new products and making acquisitions to consolidate their market positions across the globe. The competitive landscape includes an analysis of a few international as well as local companies that hold the market shares and are well known, including Allergan Plc, Pfizer Inc, AbbVie Inc, TherapeuticsMD Inc, and Ferring Holding SA, among others.
Gynecology Drugs Market Leaders
-
Ferring Holding SA
-
TherapeuticsMD Inc.
-
AbbVie Inc.
-
Pfizer Inc.
-
GSK plc
*Disclaimer: Major Players sorted in no particular order
Gynecology Drugs Market News
- February 2023: GSK plc announced that the United States Food Drug Administration (FDA) granted full approval for Jemperli for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer.
- September 2022: Lynparza received approval in China as the first line of maintenance treatment with bevacizumab for homologous recombination deficiency (HRD)-positive advanced ovarian cancer.
Gynecology Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Burden of Gynecological Diseases
- 4.2.2 Rise in Healthcare Awareness Along with Increasing Ageing Female Population
-
4.3 Market Restraints
- 4.3.1 High Cost and Stringent Regulatory Framework that Delays the Approval of the Drugs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Therapeutics
- 5.1.1 Hormonal Therapy
- 5.1.2 Non-hormonal Therapy
-
5.2 By Indication
- 5.2.1 Gynecology Cancers
- 5.2.2 Menopausal Disorder
- 5.2.3 Polycystic Ovary Syndrome
- 5.2.4 Contraception
- 5.2.5 Other Indications
-
5.3 By Distribution Channel
- 5.3.1 Hospital Pharmacies
- 5.3.2 Retail Pharmacies
- 5.3.3 Online Pharmacies
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc.
- 6.1.2 AbbVie Inc.
- 6.1.3 TherapeuticsMD Inc.
- 6.1.4 Ferring Holding SA
- 6.1.5 Lupin Pharmaceuticals Inc
- 6.1.6 Johnson & Johnson
- 6.1.7 Eli Lilly and Company
- 6.1.8 Bayer AG
- 6.1.9 GSK plc
- 6.1.10 Abbott Laboratories Ltd.
- 6.1.11 AstraZeneca
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityGynecology Drugs Industry Segmentation
Gynecological drugs are used to treat ailments related to the female reproductive system. A major shift in the lifestyles of women led to a rise in the prevalence of gynecological disorders affecting the functioning of the uterus, ovaries, and appendages.
The gynecology drugs market is segmented by therapeutics (hormonal therapy and non-hormonal therapy), by indication (gynecology cancers, menopausal disorder, polycystic ovary syndrome, contraception, and other indications), by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Therapeutics | Hormonal Therapy | |
| Non-hormonal Therapy | ||
| By Indication | Gynecology Cancers | |
| Menopausal Disorder | ||
| Polycystic Ovary Syndrome | ||
| Contraception | ||
| Other Indications | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Gynecology Drugs Market Research FAQs
What is the current Global Gynecology Drugs Market size?
The Global Gynecology Drugs Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Global Gynecology Drugs Market?
Ferring Holding SA, TherapeuticsMD Inc., AbbVie Inc., Pfizer Inc. and GSK plc are the major companies operating in the Global Gynecology Drugs Market.
Which is the fastest growing region in Global Gynecology Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Gynecology Drugs Market?
In 2024, the North America accounts for the largest market share in Global Gynecology Drugs Market.
What years does this Global Gynecology Drugs Market cover?
The report covers the Global Gynecology Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Gynecology Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Gynecological Drugs Industry Report
Statistics for the 2024 Gynecological Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Gynecological Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
